City of Hope to Present 49 Abstracts at ASCO 2026, Highlighting Immunotherapy and Precision Medicine Breakthroughs — City of Hope

Event summary

City of Hope will present 49 abstracts at the 2026 ASCO Annual Meeting, including new findings on immunotherapy and precision medicine across various cancer types.
Key presentations include updated efficacy and safety data for Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory large B-cell lymphoma.
City of Hope's chief scientific officer, John Carpten, Ph.D., has been named the recipient of the 2026 Allen Lichter Visionary Leader Award from ASCO.
Three City of Hope faculty have been named Fellow of the American Society of Clinical Oncology (FASCO).

The big picture

City of Hope's robust presence at ASCO 2026 underscores its leadership in cancer research and treatment, particularly in immunotherapy and precision medicine. The organization's commitment to translating discovery into real progress for patients aligns with broader industry trends towards personalized cancer care. With a growing national system and numerous accolades, City of Hope is positioning itself as a key player in the oncology space.

What we're watching

Clinical Impact: How the updated efficacy and safety data from the SUNMO study will influence treatment strategies for relapsed/refractory large B-cell lymphoma.
Regulatory Dynamics: Whether the phase 1, first-in-human study evaluating ABBV-969 in metastatic castration-resistant prostate cancer will advance to further clinical trials.
Market Positioning: The pace at which City of Hope can translate its research findings into commercialized therapies, given its strong presence at ASCO 2026.